ESMO 2026 - Breast Cancer After CDK4/6 with Dr. Nathalie LeVasseur

Putting trial design in the context of everyday care, Dr. Nathalie LeVasseur discusses FOURLIGHT-1, postMONARCH and biomarker-guided treatment choices after CDK4/6 progression in HR+/HER2-negative metastatic breast cancer.